Related Experiment Videos
Receptor strategies in pancreatitis
1University of California, San Francisco.
Abstract:
A variety of receptors on pancreatic acinar and duct cells regulate both pancreatic exocrine secretion and intracellular processes. These receptors are potential sites of action for therapeutic agents in the treatment of pancreatitis. Cholecystokinin (CCK) receptor antagonists, which may reduce the level of metabolic "stress" on acinar cells, have been shown to mitigate the severity of acute pancreatitis in a number of models. Not all studies have shown a benefit, however, and differences may exist between different structural classes of antagonists. Because increased pancreatic stimulation due to loss of feedback inhibition of CCK has been proposed to contribute to the pain of some patients with chronic pancreatitis, CCK receptor antagonists could also be of benefit in this setting. Somatostatin and its analogs diminish pancreatic secretion of water and electrolytes and have been effective in treating pancreatic fistulas and pseudocysts. These agents are also being evaluated for their ability to reduce pain in chronic pancreatitis (perhaps by reducing ductal pressure by diminishing secretory volume) and mitigating the severity of acute pancreatitis (possibly by reducing the metabolic load on acinar cells). Recently described secretin receptor antagonists may also have therapeutic value as a means of selectively inhibiting pancreatic secretion of water and electrolytes.
Insights
Therapeutic agents targeting pancreatic receptors, such as cholecystokinin (CCK) receptor antagonists and somatostatin analogs, show promise for treating acute and chronic pancreatitis by modulating pancreatic secretion and cellular stress.
Area of Science:
- Gastroenterology and Hepatology
- Molecular Pharmacology
Background:
- Pancreatic acinar and duct cells possess diverse receptors regulating exocrine secretion and intracellular functions.
- These receptors represent key targets for therapeutic interventions in pancreatitis management.
- Cholecystokinin (CCK) receptor antagonists may alleviate acute pancreatitis by reducing acinar cell metabolic stress.
Purpose of the Study:
- To explore the therapeutic potential of targeting pancreatic receptors for pancreatitis treatment.
- To evaluate the efficacy of CCK receptor antagonists in acute and chronic pancreatitis.
- To assess the role of somatostatin analogs and secretin receptor antagonists in managing pancreatic disorders.
Main Methods:
- Review of studies investigating CCK receptor antagonists in various pancreatitis models.
- Analysis of the effects of somatostatin and its analogs on pancreatic secretion and clinical outcomes.
- Examination of emerging data on secretin receptor antagonists for pancreatic secretion inhibition.
Main Results:
- CCK receptor antagonists demonstrated mitigation of acute pancreatitis severity in several models, though benefits varied by antagonist class.
- Loss of CCK feedback inhibition is implicated in chronic pancreatitis pain, suggesting a role for CCK antagonists.
- Somatostatin analogs effectively treat pancreatic fistulas and pseudocysts and are being evaluated for pain reduction in chronic pancreatitis and severity mitigation in acute pancreatitis.
Conclusions:
- Targeting pancreatic receptors, particularly CCK receptors, offers a promising therapeutic strategy for acute and chronic pancreatitis.
- Somatostatin analogs are valuable for managing complications like fistulas and pseudocysts and may help with pain and severity.
- Secretin receptor antagonists represent a novel approach for selective inhibition of pancreatic secretion, potentially aiding in pancreatitis treatment.